Who are Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): carboplatin paclitaxel bevacizumab, FOLFOX/ FOLFIRI with bevacizumab, FOLFOXIRI with bevacizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-cisplatin-carboplatin-paclitaxel-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab (Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with anti-angiogenic monoclonal antibody. Area: Oncology.

phase 3 Chemotherapy combination with anti-angiogenic monoclonal antibody DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab (Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab) — Lee's Pharmaceutical Limited. This combination regimen uses platinum-based chemotherapy and a taxane to damage cancer cell DNA, combined with an anti-angiogenic monoclonal antibody to block tumor blood vessel formation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab TARGET	Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab)
carboplatin paclitaxel bevacizumab	carboplatin paclitaxel bevacizumab	Gruppo Oncologico Italia Meridionale	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab)
FOLFOX/ FOLFIRI with bevacizumab	FOLFOX/ FOLFIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (chemotherapy); VEGF (bevacizumab)
FOLFOXIRI with bevacizumab	FOLFOXIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with anti-angiogenic monoclonal antibody class)

Dutch Colorectal Cancer Group · 2 drugs in this class
Gruppo Oncologico Italia Meridionale · 1 drug in this class
Lee's Pharmaceutical Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-cisplatin-carboplatin-paclitaxel-bevacizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab